Goodwin Procter advised the initial purchasers on the deal.Sarepta Therapeutics, Inc. announced its Rule 144A offering of 1.25% Convertible Senior Notes due 2027. The $1.15 billion offering…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Martina Bellini
…
This content is for Standard 1 Year members only. LoginJoin Now